Skip to main content

dupilumab (Dupixent®)

 

Status: Recommended with restrictions

Dupilumab (Dupixent®) is recommended as an option for restricted use within NHS Wales.

Dupilumab (Dupixent®) is licensed in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.

Dupilumab (Dupixent®) is restricted for use in a subpopulation of the licensed indication in line with the National Institute of Health and Care Excellence recommendation for the restricted use of dupilumab for treating severe asthma with type 2 inflammation (TA751).

Dupilumab (Dupixent®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

 Final Recommendation: dupilumab (Dupixent) 4017 (PDF, 426Kb)

Medicine details

Medicine name dupilumab (Dupixent®)
Formulation 200 mg solution for injection, 300 mg solution for injection
Reference number 4017
Indication

Indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO) who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment

Company Sanofi-Aventis Ltd
BNF chapter Respiratory system
Submission type Licence extension for paediatric use
Status Recommended with restrictions
Advice number 1522
AWMSG meeting date 14/09/2022
Date of issue 03/10/2022
Commercial arrangement PAS
Further information

See NICE TA751: Dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over

Follow AWTTC: